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Background: Histone deacetylase inhibitors (HDACis) like vorinostat are promising radiosensitisers in prostate cancer, but their
effect under hypoxia is not known. We investigated gene expression associated with radiosensitisation of normoxic and hypoxic
prostate cancer cells by vorinostat.
Methods: Cells were exposed to vorinostat under normoxia or hypoxia and subjected to gene expression profiling before
irradiation and clonogenic survival analysis.
Results: Pretreatment with vorinostat led to radiosensitisation of the intrinsically radioresistant DU 145 cells, but not the
radiosensitive PC-3 and 22Rv1 cells, and was independent of hypoxia status. Knockdown experiments showed that the
sensitisation was not caused by repression of hypoxia-inducible factor HIF1 or tumour protein TP53. Global deregulation of DNA
repair and chromatin organisation genes was associated with radiosensitisation under both normoxia and hypoxia.
A radiosensitisation signature with expression changes of 56 genes was generated and valid for both conditions. For eight
signature genes, baseline expression also correlated with sensitisation, showing potential as pretreatment biomarker. The hypoxia
independence of the signature was confirmed in a clinical data set.
Conclusions: Pretreatment with HDACi may overcome radioresistance of hypoxic prostate tumours by similar mechanisms as
under normoxia. We propose a gene signature to predict radiosensitising effects independent of hypoxia status.
Relapse is a major clinical problem in the radiotherapy of
localised, high-risk prostate cancer, where more than half of the
patients will have a biochemical relapse within 5 years (Cooper and
Sanfilippo, 2015). Strategies for radiosensitisation are therefore
highly warranted, especially in patients with hypoxic tumours, as
hypoxia is both frequent (Parker et al, 2004; Carnell et al, 2006;
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Ragnum et al, 2015) and an important cause of treatment failure
(Milosevic et al, 2012; Turaka et al, 2012) in this disease. Histone
deacetylease inhibitors (HDACis) can block subsets of isoenzymes
belonging to the HDAC superfamily, and inhibitors targeting class
I and II HDACs have emerged as promising epigenetic drugs for
radiosensitisation (Ree et al, 2010; Smits et al, 2014). Several of
them, including vorinostat and valproic acid (VPA), are currently
evaluated in combination trials with radiotherapy (Groselj et al,
2013), and a phase 1 trial has been completed on prostate cancer
(NCT00670553). Discovery of biomarkers for selection of patients
to the combination trials is crucial, but no biomarkers exist or are
even ready for clinical testing (Smits et al, 2014). A better
understanding of the mechanisms underlying the radiosensitising
effect is needed (Groselj et al, 2013). In particular, only few studies
report on a possible sensitisation of hypoxic cells (Saelen et al,
2012), and current knowledge of the molecular changes by HDACi
under hypoxia is scarce and based on studies of individual
candidate proteins (Kong et al, 2006; Yu et al, 2012).
Class I/II HDACis act by increasing acetylation of histones and
other proteins, leading to alterations in the cellular gene expression
program, impaired cell proliferation and induction of apoptosis
(Bose et al, 2014). Downregulation of DNA repair enzymes,
alterations in chromatin structure and cell cycle perturbations may
affect the cellular radiosensitivity and have been proposed to be
involved in the radiosensitising effect (Groselj et al, 2013) that also
appears to be dependent on the mutation status of the tumour
suppressor protein TP53 (Chen et al, 2009, 2011). The HDACis
may further repress signalling through the hypoxia-inducible factor
1 (HIF1) (Chen and Sang, 2011), an important transcription factor
in the pathogenesis of prostate cancer that may play a role in the
radiation response (Moeller and Dewhirst, 2006). Under hypoxia,
downregulation of the HIF1 a-subunit (HIF1A) and selected HIF1
target genes by HDACis has been demonstrated (Kong et al, 2006;
Yu et al, 2012). However, a clear and comprehensive picture of the
molecular effect of the inhibitors under hypoxia and its relation-
ship to radiosensitivity is still lacking.
The present work was conducted to better understand the
potential of HDACis as radiosensitiser in hypoxic prostate cancer.
We aimed to compare the radiosensitising properties of vorinostat
in prostate cancer cell lines grown under normoxic and hypoxic
conditions and identify a gene expression signature associated with
a possible sensitising effect. Three prostate cancer cell lines with
different intrinsic radiosensitivity were treated with vorinostat
before radiation. To identify genes with a role in vorinostat-
mediated radiosensitisation, a global gene expression analysis was
performed where we addressed the importance of HIF1 and TP53
repression and searched for differentially affected DNA repair and
chromatin organisation genes across the cell lines.
MATERIALS AND METHODS
Cell cultures. The prostate cancer cell lines DU 145, PC-3 and
22Rv1 were included. Cell line identity was confirmed by
STR/DNA profiling using PowerPlex 21 (Promega, Madison, WI,
USA) by Eurofins Genomics (Ebersberg, Germany). All cell lines
are classified as androgen independent (van Bokhoven et al, 2003).
The DU 145 has mutation at both alleles of TP53 and shows strong
protein expression, PC-3 expresses no TP53 because of a truncated
translation product, whereas 22Rv1 has heterozygote mutation and
shows weak expression of wild-type TP53 (van Bokhoven et al,
2003). The DU 145 has been shown to be more radioresistant than
PC-3 and 22Rv1 (Leith et al, 1993; Hennessey et al, 2013). The cells
were kept in RPMI-1640 medium (Sigma-Aldrich, St Louis,
MO, USA) supplemented with 10% fetal bovine serum, 1%
penicillin–streptomycin and 1% L-glutamine, incubated at 37 1C in
humidified room air with 5% CO2 and tested for mycoplasma on a
routine basis. Automatic cell counting was performed using the
Coulter Counter Z2 (Beckman Coulter, Brea, CA, USA).
Lentiviral production and knockdown of HIF1A and TP53.
Lentiviral-based vectors for RNA interference-mediated gene
silencing (FSVsi) consisted of an U6 promoter for expression of
short-hairpin RNAs (shRNAs) against HIF1A (50-CCAGTTAT
GATTGTGAAGTTA-30) or TP53 (50-GTCCAGATGAAGCTCC
CAGAA-30) and the Venus variant of yellow fluorescent protein
(YFP) under the control of an SV40 promoter for monitoring
transduction efficiency. Oligonucleotides to produce plasmid-
based shRNA were cloned into the FSVsi vector using AgeI–
BamHI restriction sites. Lentiviral particles were produced in 293T
human embryonic kidney cells co-transfected by the calcium
phosphate method as previously described (Li et al, 2012) with the
above plasmid plus plasmids coding for the envelope and the
packaging systems, VSV-G and D8.9, respectively.
The 293T cells were allowed to produce lentiviral particles for
3–4 days. Culture medium was then collected, centrifuged for
10min at 2500 r.p.m., filtered through a 0.45mm filter (Millipore,
Bedford, MA, USA) and concentrated by centrifugation through a
filter column of 100 kDa (VWR International LLC, West Chester,
PE, USA) for 1 h at 4000 r.p.m. The DU 145 cells were incubated
overnight in the presence of medium containing lentiviral particles.
Then, medium was replaced with fresh medium and cells were
incubated for two additional days to allow endogenous protein
knockdown.
Treatments. Cells were seeded in triplicates 12 h before treatment
using 6-well plates and T25 cell flasks with sealable caps (both from
Nunc, Penfield, NY, USA) for the normoxia and hypoxia treatment
arm, respectively. Vorinostat (Cayman Chemical Company, Ann
Arbor, MI, USA) was diluted in DMSO and added to the medium
at a dose of 1 mM for 24 h before irradiation. This treatment
condition has been reported to induce histone hyperacetylation in
prostate cancer cell lines (Kortenhorst et al, 2008), and
corresponding drug concentration has been found achievable in
patients (Ramalingam et al, 2007).
The humidified hypoxia chamber In Vivo2 200 (Ruskinn
Technology, Brigend, UK) with integrated gas concentration
measurements was used to create a model system for tumour
hypoxia. Cells were exposed to 0.2% O2 and 5% CO2 for 24 h
before irradiation. This oxygen level has been shown to cause
radioresistance and alter DNA damage signalling of prostate cancer
cell lines (Chan et al, 2007; Stewart et al, 2011). To avoid
reoxygenation of hypoxia-treated cells before irradiation, the
sealable caps on cell flasks were closed inside the hypoxia chamber
before transport to the irradiation machine. Single-fraction
irradiation of 2 or 5Gy was delivered by a 160 kV X-ray generator
(Faxitron, Tucson, AZ, USA) with a dose rate of 1Gymin 1.
Parallel normoxic and hypoxic cell cultures without exposure to
irradiation were harvested at 70–80% confluence for analysis of cell
cycle distribution, gene expression and protein expression. To
avoid reoxygenation, samples from the hypoxia treatment arm
were harvested inside the hypoxia chamber using reagents that had
been exposed to 0.2% O2 for 1–2 h, except for the ice-cold
methanol used for cell fixation.
Clonogenic assay. Clonogenic assay was performed to measure
surviving fraction of the cells after vorinostat treatment, knock-
down of HIF1A or TP53 and/or irradiation as described previously
(Saelen et al, 2012). Fresh medium without vorinostat or solvent
was added to the cells after treatment. The cells were incubated
under normoxia in 6-well plates (normoxic treatment arm) or
unsealed T25 cell flasks (hypoxia treatment arm) for 10–14 days
before aspiration of medium, fixation in ice-cold methanol and
staining with 0.05% crystal violet. Colonies of 450 cells were
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considered to stem from clonogenic cells and counted. Plating
efficiencies (mean±s.e.m.) were 67±3% (DU 145), 70±7%
(PC-3) and 32±2% (22Rv1).
Cell cycle distribution. Cell cycle distributions following combina-
tions of vorinostat and hypoxia treatments were analysed in an
LSRII flow cytometer (BD Biosciences, Mountain View, CA, USA)
using the detergent-trypsin method developed by Vindelov et al
(1983). Approximately 2 106 cells were washed with PBS, and
nuclei were prepared and stained with propidium iodide as
previously described (Vindelov et al, 1983) using 900ml of solution
A and 750ml of solutions B and C. Cell doublets were excluded from
analysis in the BD FACSDiva software (BD Biosciences, Franklin
Lakes, NJ, USA) by using area and width of the DNA signal.
Fraction of cells in the different cell cycle phases was assessed using
ModFit version 5.11 (Verity Software House, Topsham, ME, USA)
and FlowJo (Tree Star Inc., Ashland, OR, USA).
Illumina gene expression analysis. Gene expression analysis of
three biological replicates of each cell line was performed using
HumanHT-12 v4 bead arrays from Illumina (San Diego, CA, USA)
with B48 000 probes. Total RNA was extracted with the
QiaShredder and RNeasy Mini Kits (Qiagen, Oslo, Norway)
following the manufacturer’s instructions. Quality control of
RNA was performed with Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA). RNA amplification, cRNA
synthesis, hybridisation, scanning and quantile normalisation
were performed as previously described (Halle et al, 2011).
Log2-transformed data were used in further analysis. The data
have been deposited to the Gene Expression Omnibus (GEO)
repository (GSE80657). Direct HIF1 and TP53 target genes were
identified in the data sets by using a list of 276 HIF1 and 129 TP53
targets (Riley et al, 2008; Mole et al, 2009; Xia et al, 2009). Target
genes of mutant TP53 may differ from those depicted in the latter
list, but no alternative list was available.
Protein expression analysis. Whole-cell protein lysates were
prepared using Mammalian Protein Extraction Reagent (Thermo
Scientific, Oslo, Norway) supplemented with phosphatase and
protease inhibitors. To ensure complete disruption of cells,
sonication was performed. After 2–3 h of incubation at 4 1C, the
lysates were centrifuged at 15 000 r.p.m. for 15min. The super-
natant was aspirated and protein concentration was measured
using a bicinchoninic acid assay (Thermo Scientific). Protein
expression levels were evaluated by western blots, applying 20 mg
protein onto 4–20% SDS gels and overnight incubation at 4 1C with
the antibodies anti-acetylated histone H3 (polyclonal; Merck
Millipore, Billerica, MA, USA), anti-total histone H3 (clone A3S;
Merck Millipore), anti-HIF1 A (clone 54; BD), anti-EPAS1
(HIF2a) (polyclonal; Novus Biologicals, Littleton, CO, USA) and
anti-TP53 (polyclonal, sc-6243; Santa Cruz, Dallas, TX, USA). The
mouse monoclonal anti-g-tubulin (anti-TUBG1) (clone GTU-88;
Sigma-Aldrich) or anti-MCM7 (clone DCS-141, Santa Cruz) was
used as loading control. Secondary antibodies were peroxidase-
conjugated goat anti-rabbit and donkey anti-mouse (both from
Jackson ImmunoResearch Laboratories, West Grove, MA, USA).
For visualisation, chemiluminescence with SuperSignal West Dura
Extended Duration Substrate (Thermo Scientific) or LumiGLO
Chemiluminescent Substrate (KPL, Gaithersburg, MD, USA)
was used.
Clinical data. Associations between gene expression and hypoxia
in prostate tumours were investigated in a cohort of 39 patients
recruited to our ongoing FuncProst-study (NCT01464216).
Clinical information, analysis methods, gene expression and
hypoxia data have been presented in previous work (Ragnum
et al, 2015). All patients had localised, intermediate or high-risk
disease and were subjected to prostatectomy the day after i.v.
administration of the hypoxia marker pimonidazole hydrochloride
(Hydroxyprobe Inc., Burlington, MA, USA). Gene expression
profiles were assessed with HumanHT-12 v4 bead arrays
(Illumina) and hypoxia was measured by immunohistochemistry
of pimonidazole (1 : 50, Hydroxyprobe Inc.) in fresh frozen punch
biopsies taken from the surgical specimen. For the immuno-
histochemistry, antigen retrieval was performed with citrate buffer
(pH 6.0). Envision System (Dako, Glostrup, Denmark) followed
by counterstaining with haematoxylin, was used for visualisation.
Percentage of pimonidazole-positive malignant gland staining in
the histological sections was scored from 0 to 5 (0: 0%; 1: 1–10%; 2:
11–50%; 3: 51–90%; 4: 91–100%; and 5: 100%). The tumours were
divided into a more and less hypoxic group based on a median
score of 2, implying a pimonidazole-positive percentage above 10%
for the more hypoxic tumours. The gene expression profiles are
available in the GEO repository (GSE55935).
The study was reviewed and approved by The Regional
Committee for Medical and Health Research Ethics in Southeast
Norway. All patients provided informed consent for the use of
their data in the analysis.
Statistics. Statistical analyses were performed with the SigmaStat
software version 3.5 (Systat software, Erkrath, Germany) or with R,
version 3.1.1 (www.r-project.org). Differences between treatment
groups were evaluated with two-sided Student’s t-test under
conditions of normal distribution or with Mann–Whitney test
when this criterion was not met. Pearson correlation analyses were
performed to search for correlations in gene expression data. A
significance level of 0.05 was used unless otherwise indicated.
The Linear Models for Microarray Data (LIMMA) software
(Smyth, 2004) was applied to find differentially expressed genes
between groups using Benjamini–Hochberg correction for multiple
testing (Benjamini and Hochberg, 1995) with an adjusted (adj)
P-value (false discovery rate) ofo0.01 considered to be significant.
This strict adj P-value cutoff provided an appropriate number of
genes for the analysis. Gene ontology (GO) analysis was performed
with the DAVID version 6.7 software (Huang da et al, 2009),
where the same multiple testing correction was included and with
adj P-value of 0.1 as significance level. Pathway analyses of HIF1
and TP53 target genes were carried out by allowing proteins
encoded by the target genes with adj Po0.01 from the LIMMA
analysis and a 41.5-fold up- or downregulation to generate a
network of their known protein interactions from an integrated set
of 10 interaction databases (Razick et al, 2008). In the networks,
each interaction had at least one Medline citation, was experi-
mentally validated and was a physical binding protein interaction.
All interaction partners were proteins encoded by the differentially
expressed genes with adj Po0.01 from the LIMMA analysis. The
Cytoscape software (Shannon et al, 2003) was used to visualise the
networks.
RESULTS
Alterations in surviving fractions and cell cycle distributions by
vorinostat. Vorinostat treatment caused hyperacetylation of histone
H3 in all cell lines under both normoxia and hypoxia (Figure 1A),
showing that the treatment had the expected effect on histone H3. A
significant decrease in surviving fraction by vorinostat was observed
in normoxic DU 145 and PC-3 cells (P¼ 0.002 and P¼ 0.025,
respectively; Figure 1B), but not in 22Rv1. Under hypoxia, a
minor decrease in survival fraction was found only in PC-3
(P¼ 0.027; Figure 1B). Thus, at a dose of 1mM, vorinostat appeared
to have similar cytotoxic effect in DU 145 and PC-3 under both
normoxia and hypoxia, whereas 22Rv1 was more resistant.
The effect of vorinostat on cell cycle distribution also differed
across the cell lines and the same tendency was observed in the
normoxic and hypoxic treatment arms (Figure 1C; Supplementary
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Figure S1). In DU 145, fraction of cells in G2- and M-phase
increased by B10% (normoxia, P¼ 0.034; hypoxia, P¼ 0.002),
whereas no significant change in G2/M was observed in PC-3. In
22Rv1, vorinostat primarily increased the G1 fraction (normoxia,
Po0.001; hypoxia, P¼ 0.005). Hypoxia treatment alone had no
significant effects on the cell cycle distribution in DU-145 and
PC-3, but led to an increase in G1 fraction in 22Rv1 (Po0.001).
Vorinostat-mediated radiosensitisation. At single doses of 2 and
5Gy, DU 145 was the most radioresistant cell line under normoxia
followed by PC-3 and 22Rv1, in accordance with previous work
(Leith et al, 1993; Hennessey et al, 2013), and similar results were
found for the hypoxic condition (Figure 2). Pretreatment with
vorinostat under normoxia decreased the surviving fraction of DU
145 cells at both 2 and 5Gy (Po0.001; Figure 2A), whereas a much
smaller, although significant, effect was seen in 22Rv1 (Po0.001;
Figure 2C). No significant radiosensitisation was observed in PC-3
(Figure 2B). Thus, combined treatment with vorinostat made DU
145 cells equal or more radiosensitive than the intrinsically
radiosensitive PC-3 and 22Rv1 treated with radiation alone at both
radiation doses.
A pronounced radiosensitisation of DU 145 by vorinostat was
also seen under hypoxia (Po0.001; Figure 2A), whereas no
significant effects were found in PC-3 or 22Rv1 (Figure 2B and C).
In particular, pretreatment with vorinostat rendered hypoxic DU
145 cells more radiosensitive than normoxic DU 145 cells without
pretreatment and hypoxic PC-3 or 22Rv1 cells with or without
pretreatment (Figure 2). The radiosensitising effect of vorinostat
therefore appeared to differ considerably across the cell lines, and
was significant under both normoxia and hypoxia only in the most
radioresistant DU 145.
HIF1 and TP53 repression in relation to radiosensitisation. To
investigate mechanisms underlying the radiosensitising effect of
vorinostat in DU 145, we first explored whether repression of the
HIF1 and TP53 transcription factors could be involved for one or
both of the normoxic and hypoxic conditions. Global gene
expression analysis revealed a significant change (adj Po0.01) in
the expression of numerous genes by vorinostat, including several
HIF1 and TP53 targets, in normoxic and hypoxic DU 145 and
22Rv1, whereas fewer genes were affected in PC-3 (Supplementary
Figure S2). In general, the HIF1 and TP53 targets showed a greater
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Figure 1. Vorinostat-mediated changes in histone acetylation, survival fraction and cell cycle distribution. (A) Western blots of acetylated histone
H3 (AcH3) and total histone H3 under normoxia and following combinations of vorinostat (1mM, 24 h) and hypoxia exposure (0.2% O2, 24 h) in DU
145, PC-3 and 22Rv1 prostate cancer cell lines. TUBG1 was included as loading control. H¼hypoxia; N¼normoxia. (B) Survival fraction under
normoxia and following combinations of vorinostat (1 mM, 24 h) and hypoxia exposure (0.2% O2, 24 h) in DU 145, PC-3 and 22Rv1 prostate cancer
cell lines. The data for combinations of vorinostat and hypoxia exposure were normalised to the survival fraction under normoxia. (C) Fraction of
cells in different cell cycle phases under normoxia and following combinations of vorinostat (1mM, 24 h) and hypoxia exposure (0.2% O2, 24 h) in DU
145, PC-3 and 22Rv1 prostate cancer cell lines. (B and C) Columns represent mean values from three independent experiments, and bars depict
s.e.m. *Statistically significant difference.
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change in DU 145 than in the other cell lines, as demonstrated by
network analysis of the targets altered by41.5-fold (Figure 3A and
B and Supplementary Figures S3 and S4). In addition, HIF1A and
TP53 protein were downregulated by vorinostat under normoxia
and hypoxia in DU 145, but not in the others (Figure 3C and D).
Vorinostat induced no major changes in EPAS1 (HIF2a) protein
expression in any cell line. Altogether, it seemed that vorinostat
repressed HIF1 and TP53 in DU 145, but had less effect in PC-3
and 22Rv1.
Mutant TP53 has been shown to have oncogenic function in
many cancer cell lines, including DU 145 (Zhu et al, 2011). Both
HIF1 and mutant TP53 repression could therefore be a possible
cause of the vorinostat-mediated radiosensitisation of DU 145. To
test this hypothesis, the radiosensitising effect of vorinostat under
normoxia and hypoxia was studied in HIF1A and mutant TP53
knockdown DU 145 cells, for which downregulation of the proteins
was confirmed (Figure 4A). Knockdown of HIF1A decreased the
surviving fraction of normoxic, unirradiated cells by 30%
(P¼ 0.001), whereas this knockdown under hypoxia or mutant
TP53 knockdown had no significant effect on survival (Figure 4B).
Neither HIF1A nor mutant TP53 knockdown led to any
significant change in the survival of DU 145 cells upon 2 or 5Gy
irradiation (Figure 4C). Repression of HIF1A or mutant TP53
could therefore not explain the vorinostat-mediated radiosensitisa-
tion of DU 145.
Expression of DNA repair and chromatin organisation genes in
relation to radiosensitisation. Unsupervised GO analysis of all
genes differentially expressed by vorinostat was performed to
identify DNA repair and chromatin organisation genes that could
play a role in radiosensitisation. The analysis revealed six main
biological processes enriched in DU 145 and 22Rv1, including
cellular stress response with its subgroup response to DNA damage
stimulus, DNA repair and chromatin organisation (Supplementary
Table S1). Approximately the same processes were identified for
the normoxic and hypoxic condition. In PC-3, only RNA
processing and cell cycle were significantly enriched.
The DNA repair and chromatin organisation genes from the
GO analysis of DU 145 were potential mediators of the
radiosensitising effect, and their expression changes by vorinostat
were compared with those in PC-3 and 22Rv1. Many genes were
altered similarly in all three cell lines and are therefore probably
not key mediators of the effect. These included the double-strand
break repair gene CHEK1 that was significantly downregulated
under both normoxia and hypoxia. Totally, 51 DNA repair and 77
chromatin organisation genes were significantly more up- or
downregulated in DU 145 than in either PC-3 or 22Rv1 in at least
one of the normoxic or hypoxic conditions (Supplementary Tables
S2 and S3). Thus, they were candidate genes in radiosensitisation
of DU 145.
Further support for a role of the candidate genes in radio-
sensitisation was provided by comparing the expression changes in
DU 145 with the baseline expression levels (without vorinostat
treatment) in the intrinsically radiosensitive PC-3 and 22Rv1.
A significant inverse correlation was found between the expression
changes in DU 145 under normoxia and hypoxia and the baseline
difference between this cell line and PC-3 or 22Rv1, both for the
DNA repair genes (normoxia, r¼  0.40, Po0.001; hypoxia,
r¼  0.26, P¼ 0.03) and chromatin organisation genes (normoxia,
r¼  0.19, P¼ 0.04; hypoxia, r¼  0.26, P¼ 0.03). Hence,
vorinostat seemed to change the expression of the candidate
DNA repair and chromatin organisation genes in DU 145 towards
the baseline level of PC-3 and 22Rv1 cells and therefore towards a
more radiosensitive phenotype.
Generation of a hypoxia-independent gene expression signature
of radiosensitisation. All candidate genes were regulated in the
same direction by vorinostat under normoxia and hypoxia
(Supplementary Tables S2 and S3). Moreover, the expression level
differed little between the normoxic and hypoxic conditions
regardless of cell line, except for BNIP3 in chromatin organisation
(Supplementary Figure S5). In general, the candidate genes were
therefore apparently not regulated by hypoxia. Based on this
observation, we could define a radiosensitisation signature with the
expression changes of 56 of the most altered candidate genes in DU
145 compared with PC-3 and 22Rv1; 24 genes in DNA repair and
32 in chromatin organisation. These genes were significantly
altered by vorinostat (adj Po0.01, LIMMA) in DU 145 and
showed a larger change in this cell line than in the others (Po0.05,
t-test) under both normoxia and hypoxia (Figure 5A and
Supplementary Tables S2 and S3). The signature included
both up- and downregulated genes, reflecting a pronounced
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Figure 2. Radiosensitising effect of vorinostat. Survival fraction
following irradiation (IR) under normoxia and combinations of
vorinostat (1mM, 24 h) and hypoxia exposure (0.2% O2, 24 h) in DU 145
(A), PC-3 (B) and 22Rv1 (C) prostate cancer cell lines. Points represent
mean value from at least three independent experiments, and bars
depict s.e.m. *Statistically significant difference compared with
normoxia solvent control; **statistically significant differences
compared with hypoxia solvent control.
Hypoxia and radiosensitisation by HDACi BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2016.278 933
deregulation of the DNA repair and chromatin organisation
processes in association with the vorinostat-mediated radiosensitisation.
To investigate whether any of the signature genes could serve as
pretreatment biomarker for prediction of a radiosensitising effect
already before the onset of vorinostat treatment, we search for
baseline gene expression characteristics of the radioresistant DU
145 phenotype, for which a radiosensitising effect was observed, as
compared with the radiosensitive PC-3 and 22Rv1 phenotype with
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Figure 3. Vorinostat-mediated changes in HIF1 and TP53 signalling. (A and B) First-degree protein interaction networks of the direct HIF1 (A) and
TP53 (B) target genes with41.5-fold change following vorinostat exposure (1 mM, 24 h) under hypoxic conditions (0.2% O2, 24 h) in DU 145, PC-3
and 22Rv1 prostate cancer cell lines. Large circles indicate direct interaction partners of HIF1 and TP53. The first-degree interaction partners
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no radiosensitisation. This comparison identified a subset of eight
signature genes; ABL1, APEX1, CRY1, NEIL2 and VCP in DNA
repair and H1F0, H3F3B and HDAC1 in chromatin organisation,
for which a significant difference (Po0.01, LIMMA) in baseline
expression was seen between DU 145 and both PC-3 and 22Rv1
(Figure 5B). Hence, a high expression of ABL1, APEX1, NEIL2 and
VCP and low expression of CRY1, H1F0, H3F3B and HDAC1
represented a pretreatment predictor of a radioresistant phenotype
for sensitisation with vorinostat regardless of hypoxia status.
To confirm that the radiosensitisation signature, including the
eight biomarker genes, was also independent of hypoxia in a
clinical setting, we compared the expression level of the 56 genes
between pimonidazole-positive and -negative prostate tumours in
patients (Figure 6). No difference between the two groups was seen
for any of the genes, consistent with our cell line results.
DISCUSSION
Pretreatment of prostate cancer cells with clinically relevant doses
of the class I/II HDACi vorinostat led to significant radio-
sensitisation under both normoxic and hypoxic conditions. This
effect was observed in the most radioresistant DU 145 cell line that
became as sensitive as the radiosensitive PC-3 and 22Rv1 lines.
Our results encourage further development of drugs inhibiting
class I/ II HDACs for use in combination with radiation to
counteract the poor response of the most radioresistant prostate
tumours and, in particular, to overcome a major problem in
radiotherapy caused by hypoxia. Approval by the Food and Drug
Administration (FDA) and ongoing testing of vorinostat in clinical
studies (Groselj et al, 2013) make this drug especially interesting
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Figure 4. Radiosensitising effect of HIF1A and mutant TP53 knockdown. (A) Western blots of HIF1A and TP53 under normoxia and following
hypoxia exposure (0.2% O2, 24 h) in DU 145 prostate cancer cell line without ( ) and with (þ ) lentiviral-mediated knockdown of HIF1A and mutant
TP53. TUBG1 and MCM7 were included as loading controls. The experiment was repeated three times with similar results (data not shown).
(B) Survival fraction under normoxia and hypoxia (0.2% O2, 24 h) in DU 145 prostate cancer cell line without (ctl) and with lentiviral mediated
knockdown of HIF1A (HIF1A shRNA) and mutant TP53 (TP53 shRNA). The data for hypoxia and knockdown were normalised to the survival fraction
under normoxia. Columns represent mean values from three independent experiments, and bars depict s.e.m. *Statistically significant difference.
(C) Survival fraction following irradiation (IR) under normoxia and hypoxia exposure (0.2% O2, 24 h) in DU 145 prostate cancer cell line without (ctl)
and with lentiviral-mediated knockdown of HIF1A (HIF1A shRNA) and mutant TP53 (TP53 shRNA). Points represent mean value from at least three
independent experiments, and bars depict s.e.m.
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for the exploration of radiosensitising properties. Moreover, new
drugs are in pipeline, although none of those tested in patients
have so far demonstrated superior clinical activity or more
favourable toxicity profiles (West and Johnstone, 2014). Regardless
of cell line and radiosensitisation, HDACi treatment led to
deregulation of HIF1, TP53, DNA repair and chromatin organisa-
tion genes. However, to the best of our knowledge, our work is the
first to identify a gene expression signature associated with a
radiosensitising effect of the HDACi treatment and demonstrate its
independence of hypoxia status.
The HDACi treatment had a large effect on HIF1 and TP53 in
DU 145. Previous work has shown that HIF1 may play a role in the
cellular radiation response, although both radioprotective and
radiosensitising effects have been demonstrated, and the under-
lying mechanisms are not clarified (Moeller et al, 2007). Moreover,
various lines of evidence indicate that mutations in TP53 may lead
to gain of function and resistance to anticancer treatment,
including radiation (Oren and Rotter, 2010). However, it appeared
from our knockdown experiments that neither HIF1 nor TP53
repression alone could explain the radiosensitising effects of
HDAC inhibition. It is possible that a HDACi-mediated cell cycle
redistribution could have played a role in the radiosensitisation of
DU 145. The HDACi treatment caused accumulation of DU 145
cells in G2 and M phases, which are the most radiosensitive phases
(Joiner and van der Kogel, 2009), whereas no such accumulation
was observed in PC-3 and 22Rv1. However, this accumulation led
to an increase in the G2/M fraction of only 10%, and this is not
enough to explain the entire difference of approximately one order
of magnitude in radiosensitisation between DU 145 and the other
cell lines.
By comparing HDACi-mediated gene expression changes on a
global scale, significant differences in the expression of numerous
DNA repair and chromatin organisation genes across the cell lines
were identified, most likely contributing to radiosensitisation in a
collective manner. This hypothesis was supported by the finding
that HDACi treatment changed the expression of these genes in
DU 145 towards the level in the more radiosensitive PC-3 and
22Rv1. Many of the same genes were affected by vorinostat under
both normoxia and hypoxia, and only few of them were responsive
to hypoxia exposure alone as confirmed in a clinical data set.
It therefore seems that the mechanisms underlying the radio-
sensitising effect are independent on the hypoxia status of the
tumour cells. This observation is important for the use of HDACi
in the clinic, as pretreatment identification of the hypoxic tumours
would not be necessary.
The 56-gene signature may provide information about the
mechanisms underlying the sensitising effect. In particular, the
signature contained downregulated genes with a regulatory role in
DNA repair pathways, such as genes encoding the ubiquitin-
selective segregase VCP and the ABL tyrosine kinase. These
proteins orchestrate double-strand break repair by regulating
proteins like TP53BP1, BRCA1, RAD51 and RAD52 (Colicelli,
2010; Meerang et al, 2011). Notably, genes encoding these
downstream proteins have been found to be downregulated by
class I/II HDACis in previous work (Lee et al, 2010; Kachhap et al,
2010), but their regulators, VCP and ABL1, have not been
mentioned. In addition, the signature contained downregulated
genes involved in the first steps of base excision repair (Curtin,
2012), including genes encoding the multifunctional DNA repair
enzyme APEX1 and the members of the Nei-like protein family,
NEIL2 and NEIL3, suggesting that deregulation of this pathway
also plays a role. In accordance with this, the importance of APEX1
for the radiosensitivity of DU 145 has been demonstrated by
knockdown experiments (Skvortsova et al, 2008), although the
radiosensitising effect was not as large as observed in our
study. The genes EEPD1 and CRY1 were among the upregulated
DNA repair genes and appear to be involved in DNA damage
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Figure 5. Gene expression signature of radiosensitisation. (A) Change
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sensing and stabilisation of genotoxic stress (Papp et al, 2015;
Wu et al, 2015).
The chromatin organisation genes included the downregulated
H2AFY2 and upregulated H3F3B genes, encoding the variant
histone H2A (macroH2A) and H3 (H3.3), respectively, suggesting
reorganisation of the chromatin in DU 145 by HDACi towards a
more open and transcriptionally active structure (Melters et al,
2015). Hence, increased acetylation of histones by HDACis results
in loosening of chromatin and better accessibility for replication
and transcription. It has been shown that the number of double-
strand breaks after irradiation is enhanced by chromatin relaxation
possibly because of more accessible DNA attack sites for the
radicals (Lavelle and Foray, 2014). Chromatin reorganisation by
HDACi treatment may therefore have increased the radiation-
induced DNA damage in DU 145 cells. Interpretation of the
chromatin organisation data is, however, difficult, as many genes,
including HDAC1, may act as both tumour suppressor gene
and oncogene, depending on cell type and state (West and
Johnstone, 2014), and also affect the cellular repair capacity
(Robert et al, 2011).
Monitoring expression changes of the signature genes during
HDACi treatment may indicate a possible radiosensitisation before
the onset of radiotherapy, and might be of clinical value. In
addition, a subset of eight genes showed differences in baseline
expression across the cell lines and might be useful in the initial
treatment planning to decide upon a possible pretreatment with
HDACi. Hence, high baseline expression of DNA repair genes
(ABL1, VCP, APEX1, NEIL2) in DU 145 as compared with PC-3
and 22Rv1 suggests higher repair capacity of the former cell line,
whereas low H3F3B expression may indicate a close chromatin
structure. It could be speculated that these baseline characteristics
play a role in the intrinsic radioresistance of DU 145 and that
targeting of these characteristics by HDACi is an efficient way to
radiosensitise the cells. The association between baseline expres-
sion and radioresistance could be tested retrospectively in stored
tumour specimens from prostate cancer patients treated with
radiotherapy and with known outcome data. Moreover, for the
HDACi-mediated radiosensitisation, it would be of interest to
evaluate pretreatment expression level of the 8 genes as well as the
expression changes during HDACi pretreatment of all 56 genes in
specimens collected in combination trials with radiotherapy.
ACKNOWLEDGEMENTS
Financial support was provided by the European Union 7th
Framework Program (Grant No. 222741-METOXIA), the Norwe-
gian Cancer Society (Grant No. 107438 - PR-2007-0179) and The
South-Eastern Norway Regional Health Authority (Grant No.
2015020).
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J R Statist Soc B 57: 289–300.
Bose P, Dai Y, Grant S (2014) Histone deacetylase inhibitor (HDACI)
mechanisms of action: emerging insights. Pharmacol Ther 143(3):
323–336.
7 8 9 10 11 12 13 7 8 9 10 11 12 13
7
8
9
10
11
12
13
7
8
9
10
11
12
13
G
en
e 
ex
pr
es
sio
n,
 p
im
o+
 (lo
g 2
)
Gene expression, pimo–(log2)
DNA repair Chromatin organisation
Pimo– Pimo+
A
B
Figure 6. Expression of signature genes in relation to hypoxia in prostate tumours in patients. (A) Histological section of tumour biopsy from two
different prostate cancer patients, showing negative (pimo ) and positive (pimoþ ) pimonidazole staining. (B) Expression of signature genes in
pimoþ vs pimo tumours. Data of 24 DNA repair genes and 32 chromatin organisation genes are shown in the left and right panel, respectively.
Points represent mean value of 21 pimoþ and 18 pimo tumours, bars depict s.e.m. and stippled lines indicate limits for two-fold difference
between the pimoþ and pimo groups.
Hypoxia and radiosensitisation by HDACi BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2016.278 937
Carnell DM, Smith RE, Daley FM, Saunders MI, Bentzen SM, Hoskin PJ
(2006) An immunohistochemical assessment of hypoxia in prostate
carcinoma using pimonidazole: implications for radioresistance. Int J
Radiat Oncol Biol Phys 65: 91–99.
Chan N, Milosevic M, Bristow RG (2007) Tumor hypoxia, DNA repair and
prostate cancer progression: new targets and new therapies. Future Oncol
3: 329–341.
Chen S, Sang N (2011) Histone deacetylase inhibitors: the epigenetic
therapeutics that repress hypoxia-inducible factors. J Biomed Biotechnol
2011: 197946.
Chen X, Wong JY, Wong P, Radany EH (2011) Low-dose valproic acid
enhances radiosensitivity of prostate cancer through acetylated p53-
dependent modulation of mitochondrial membrane potential and
apoptosis. Mol Cancer Res 9(4): 448–461.
Chen X, Wong P, Radany E, Wong JY (2009) HDAC inhibitor, valproic acid,
induces p53-dependent radiosensitization of colon cancer cells. Cancer
Biother Radiopharm 24(6): 689–699.
Colicelli J (2010) ABL tyrosine kinases: evolution of function, regulation, and
specificity. Sci Signal 3(139): re6.
Cooper BT, Sanfilippo NJ (2015) Concurrent chemoradiation for high-risk
prostate cancer. World J Clin Oncol 6(4): 35–42.
Curtin NJ (2012) DNA repair dysregulation from cancer driver to therapeutic
target. Nat Rev Cancer 12(12): 801–817.
Groselj B, Sharma NL, Hamdy FC, Kerr M, Kiltie AE (2013) Histone
deacetylase inhibitors as radiosensitisers: effects on DNA damage
signalling and repair. Br J Cancer 108(4): 748–754.
Halle C, Lando M, Svendsrud DH, Clancy T, Holden M, Sundfør K,
Kristensen GB, Holm R, Lyng H (2011) Membranous expression of
ectodomain isoforms of the epidermal growth factor receptor predicts
outcome after chemoradiotherapy of lymph node-negative cervical cancer.
Clin Cancer Res 17: 5501–5512.
Hennessey D, Martin LM, Atzberger A, Lynch TH, Hollywood D, Marignol L
(2013) Exposure to hypoxia following irradiation increases radioresistance
in prostate cancer cells. Urol Oncol 31: 1106–1116.
Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat
Protoc 4: 44–57.
Joiner M, van der Kogel AJ (2009) Basic Clinical Radiobiology.
Taylor & Francis Group: Boca Raton, FL, USA.
Kachhap SK, Rosmus N, Collis SJ, Kortenhorst MS, Wissing MD, Hedayati M,
Shabbeer S, Mendonca J, Deangelis J, Marchionni L, Lin J, Hoti N, Nortier
JW, DeWeese TL, Hammers H, Carducci MA (2010) Downregulation of
homologous recombination DNA repair genes by HDAC inhibition in
prostate cancer is mediated through the E2F1 transcription factor. PLoS
One 5(6): e11208.
Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J (2006) Histone deacetylase
inhibitors induce VHL and ubiquitin-independent proteasomal degradation
of hypoxia-inducible factor 1alpha. Mol Cell Biol 26(6): 2019–2028.
Kortenhorst MS, Zahurak M, Shabbeer S, Kachhap S, Galloway N,
Parmigiani G, Verheul HM, Carducci MA (2008) A multiple-loop,
double-cube microarray design applied to prostate cancer cell lines with
variable sensitivity to histone deacetylase inhibitors. Clin Cancer Res 14:
6886–6894.
Lavelle C, Foray N (2014) Chromatin structure and radiation-induced DNA
damage: from structural biology to radiobiology. Int J Biochem Cell Biol
49: 84–97.
Lee JH, Choy ML, Ngo L, Foster SS, Marks PA (2010) Histone deacetylase
inhibitor induces DNA damage, which normal but not transformed cells
can repair. Proc Natl Acad Sci USA 107(33): 14639–14644.
Leith JT, Quaranto L, Padfield G, Michelson S, Hercbergs A (1993)
Radiobiological studies of PC-3 and DU-145 human prostate cancer cells:
X-ray sensitivity in vitro and hypoxic fractions of xenografted tumors
in vivo. Int J Radiat Oncol Biol Phys 25: 283–287.
Li M, Husic N, Lin Y, Snider BJ (2012) Production of lentiviral vectors for
transducing cells from the central nervous system. J Vis Exp63e4031.
Meerang M, Ritz D, Paliwal S, Garajova Z, Bosshard M, Mailand N, Janscak P,
Hubscher U, Meyer H, Ramadan K (2011) The ubiquitin-selective
segregase VCP/p97 orchestrates the response to DNA double-strand
breaks. Nat Cell Biol 13(11): 1376–1382.
Melters DP, Nye J, Zhao H, Dalal Y (2015) Chromatin dynamics in vivo: a
game of musical chairs. Genes (Basel) 6(3): 751–776.
Milosevic M, Warde P, Me´nard C, Chung P, Toi A, Ishkanian A, McLean M,
Pintilie M, Sykes J, Gospodarowicz M, Catton C, Hill RP, Bristow R (2012)
Tumor hypoxia predicts biochemical failure following radiotherapy for
clinically localized prostate cancer. Clin Cancer Res 18: 2108–2114.
Moeller BJ, Dewhirst MW (2006) HIF-1 and tumour radiosensitivity.
Br J Cancer 95(1): 1–5.
Moeller BJ, Richardson RA, Dewhirst MW (2007) Hypoxia and radiotherapy:
opportunities for improved outcomes in cancer treatment. Cancer
Metastasis Rev 26: 241–248.
Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J,
Ratcliffe PJ (2009) Genome-wide association of hypoxia-inducible factor
(HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of
hypoxia-inducible transcripts. J Biol Chem 284(25): 16767–16775.
Oren M, Rotter V (2010) Mutant p53 gain-of-function in cancer. Cold Spring
Harb Perspect Biol 2: a001107.
Papp SJ, Huber AL, Jordan SD, Kriebs A, Nguyen M, Moresco JJ,
Yates JR, Lamia KA (2015) DNA damage shifts circadian clock time via
Hausp-dependent Cry1 stabilization. Elife 4: e04883.
Parker C, Milosevic M, Toi A, Sweet J, Panzarella T, Bristow R, Catton C,
Catton P, Crook J, Gospodarowicz M, McLean M, Warde P, Hill RP
(2004) Polarographic electrode study of tumor oxygenation in clinically
localized prostate cancer. Int J Radiat Oncol Biol Phys 58: 750–757.
Ragnum HB, Vlatkovic L, Lie AK, Axcrona K, Julin CH, Frikstad KM,
Hole KH, Seierstad T, Lyng H (2015) The tumour hypoxia marker
pimonidazole reflects a transcriptional programme associated with
aggressive prostate cancer. Br J Cancer 112(2): 382–390.
Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA,
Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP
(2007) Phase I and pharmacokinetic study of vorinostat, a histone
deacetylase inhibitor, in combination with carboplatin and paclitaxel for
advanced solid malignancies. Clin Cancer Res 13: 3605–3610.
Razick S, Magklaras G, Donaldson IM (2008) iRefIndex: a consolidated
protein interaction database with provenance. BMC Bioinformatics 9: 405.
Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M,
Abrahamsen TW, Flatmark K (2010) Vorinostat, a histone deacetylase
inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal
carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
Lancet Oncol 11: 459–464.
Riley T, Sontag E, Chen P, Levine A (2008) Transcriptional control of human
p53-regulated genes. Nat Rev Mol Cell Biol 9(5): 402–412.
Robert T, Vanoli F, Chiolo I, Shubassi G, Bernstein KA, Rothstein R,
Botrugno OA, Parazzoli D, Oldani A, Minucci S, Foiani M (2011) HDACs
link the DNA damage response, processing of double-strand breaks and
autophagy. Nature 471(7336): 74–79.
Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K
(2012) Radiosensitization by the histone deacetylase inhibitor vorinostat
under hypoxia and with capecitabine in experimental colorectal
carcinoma. Radiat Oncol 7: 165.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N,
Schwikowski B, Ideker T (2003) Cytoscape: a software environment for
integrated models of biomolecular interaction networks. Genome Res 13:
2498–2504.
Skvortsova I, Skvortsov S, Stasyk T, Raju U, Popper BA, Schiestl B, von
Guggenberg E, Neher A, Bonn GK, Huber LA, Lukas P (2008)
Intracellular signaling pathways regulating radioresistance of human
prostate carcinoma cells. Proteomics 8(21): 4521–4533.
Smits KM, Melotte V, Niessen HE, Dubois L, Oberije C, Troost EG,
Starmans MH, Boutros PC, Vooijs M, van Engeland M, Lambin P (2014)
Epigenetics in radiotherapy: where are we heading? Radiother Oncol
111(2): 168–177.
Smyth GK (2004) Linear models and empirical bayes methods for assessing
differential expression in microarray experiments. Stat Appl Genet Mol
Biol 3: e-pub ahead of print 12 February 2004.
Stewart GD, Nanda J, Katz E, Bowman KJ, Christie JG, Brown DJ,
McLaren DB, Riddick AC, Ross JA, Jones GD, Habib FK (2011) DNA
strand breaks and hypoxia response inhibition mediate the
radiosensitisation effect of nitric oxide donors on prostate cancer under
varying oxygen conditions. Biochem Pharmacol 81: 203–210.
Turaka A, Buyyounouski MK, Hanlon AL, Horwitz EM, Greenberg RE,
Movsas B (2012) Hypoxic prostate/muscle PO2 ratio predicts for outcome
in patients with localized prostate cancer: long-term results. Int J Radiat
Oncol Biol Phys 82: e433–e439.
van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE,
Miller HL, Nordeen SK, Miller GJ, Lucia MS (2003) Molecular characterization
of human prostate carcinoma cell lines. Prostate 57(3): 205–225.
BRITISH JOURNAL OF CANCER Hypoxia and radiosensitisation by HDACi
938 www.bjcancer.com |DOI:10.1038/bjc.2016.278
Vindelov LL, Christensen IJ, Nissen NI (1983) A detergent-trypsin method for
the preparation of nuclei for flow cytometric DNA analysis. Cytometry
3(5): 323–327.
West AC, Johnstone RW (2014) New and emerging HDAC inhibitors for
cancer treatment. J Clin Invest 124(1): 30–39.
Wu Y, Lee SH, Williamson EA, Reinert BL, Cho JH, Xia F, Jaiswal AS,
Srinivasan G, Patel B, Brantley A, Zhou D, Shao L, Pathak R,
Hauer-Jensen M, Singh S, Kong K, Wu X, Kim HS, Beissbarth T,
Gaedcke J, Burma S, Nickoloff JA, Hromas RA (2015) EEPD1 rescues
stressed replication forks and maintains genome stability by promoting
end resection and homologous recombination repair. PLoS Genet 11(12):
e1005675.
Xia X, Lemieux ME, Li W, Carroll JS, Brown M, Liu XS, Kung AL (2009)
Integrative analysis of HIF binding and transactivation reveals its role in
maintaining histone methylation homeostasis. Proc Natl Acad Sci USA
106: 4260–4265.
Yu J, Mi J, Wang Y, Wang A, Tian X (2012) Regulation of radiosensitivity by
HDAC inhibitor trichostatin A in the human cervical carcinoma cell line
Hela. Eur J Gynaecol Oncol 33(3): 285–290.
Zhu H, Mao Q, Lin Y, Yang K, Xie L (2011) RNA interference targeting
mutant p53 inhibits growth and induces apoptosis in DU145 human
prostate cancer cells. Med Oncol 28(Suppl 1): S381–S387.
This work is published under the standard license to publish agree-
ment. After 12 months the work will become freely available and
the license terms will switch to a Creative Commons Attribution-
NonCommercial-Share Alike 4.0 Unported License.
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
Hypoxia and radiosensitisation by HDACi BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2016.278 939
